Company intelligence / Profile preview

Cybit

Toronto, Ontario, Canadacybit.com ↗

Ownership: Private
Employees: ~55
Development stage: Other

Overview

CYB003 received FDA Breakthrough Therapy Designation in March 2024. In a Phase 2 study for MDD, it showed a remarkable efficacy at 12 months—100% response rate and a 71% remission rate among participants who received two doses. The pivotal multinational Phase 3 PARADIGM™ program is ongoing. A Phase 2 proof-of-concept study of CYB004 in GAD is underway with topline data expected Q1 2025. The pipeline also includes non-hallucinogenic neuroplastogens under investigation.

Therapeutic areas: PsychiatryNeurology
Modalities: Small moleculePsychedelic-based drugs (including deuterated tryptamines, phenethylamines)
Industry: Biotech

Partnerships

Kernel Flow neuroimaging technology partnership

Beyond the preview

Go deeper on Cybit.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cybit.

Explore the full profile